Director-affiliated entity sells over $20.5M in Ironwood Pharmaceuticals stock

summarizeSummary

A director-affiliated investment firm sold over $20.5 million worth of Ironwood Pharmaceuticals stock, representing a substantial reduction in its holdings.

check_boxKey Events

• Significant Stock Sale by Director-Affiliated Entity

  Alexander J. Denner, a Director and CIO of Sarissa Capital Management LP, reported the sale of 6,730,800 shares of Class A Common Stock for $20,530,448. The shares were held indirectly by Sarissa Capital and its funds.

• Substantial Reduction in Holdings

  This transaction represents a significant reduction in the holdings of a key institutional investor affiliated with a company director, accounting for 3.874% of Ironwood Pharmaceuticals' market capitalization.

• Routine Equity Grant

  Separately, Mr. Denner also received a grant of 4,451 shares of Class A Common Stock on March 13, 2026, as part of the non-employee director compensation policy, valued at $0.

auto_awesomeAnalysis

Alexander J. Denner, a Director of Ironwood Pharmaceuticals and Chief Investment Officer of Sarissa Capital Management LP, reported the sale of 6,730,800 shares of Class A Common Stock for a total value of $20,530,448. This significant sale, representing 3.874% of the company's market capitalization, is an institutional disposition by Sarissa Capital. While such sales can be for portfolio rebalancing, the substantial size indicates a notable reduction in exposure by a key affiliated entity. This transaction reinforces a pattern of net insider distribution over the last 90 days.